BRAF and Miyoshi myopathy: Notably, in the BRIM-3 phase 3 trial, leading to vemurafenib being approved for clinical use in patients with metastatic MM, a real-time PCR assay (cobas 4800 BRAF V600 Mutation Test, Roche Molecular Systems) was used to define mutation status [1].